The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months.
Contact phoneCarolyn Krahulik | 517.364.2811
Principal investigatorDr. Gordan Srkalovic, MD, PhD